As part of a larger effort to revive the troubled drug maker, OTSuka Pharmaceutical Industries is launching a new product line, the “God’s miracle.”

The line includes an anti-aging skin care product, an antihistamine and a supplement that can prevent the development of new infections.

Otsuka’s new God’s Miracle product is aimed at seniors in the U.S., and is priced at $25 per capsule.

The company is also developing an antiaging skin product for women, the Otsukas Health & Beauty Products, which will be released later this year.

The company has been struggling to maintain a stable product portfolio over the last few years.

The majority of its product portfolio consists of skin care products, which have become popular among young people in recent years.

However, the company has had to face challenges in its business since the start of the pandemic in 2014.

In late 2015, Oresuka Pharmaceutical started a joint venture with AstraZeneca to develop a new drug, Zyprotoid, which was supposed to be FDA-approved by the end of the year.

However the company faced a major setback after Astra Zeneca stopped all of its clinical trials.

The Otsukes Health & Beauties brand, which is aimed primarily at younger people, has become a hit among older adults, particularly those with chronic conditions.

In October of this year, the government of Israel approved Otsuku’s plan to start a clinical trial for ZyProtoid.

However, a few weeks later, Astra halted all of their clinical trials, and Otsuko lost its license to conduct trials on ZyPR.

Since then, Otersuka has faced multiple challenges, from losing sales and profits, to the fact that it has struggled to sell its skin care line, which has suffered a number of setbacks.

In a press release, Oursuka Pharmaceutical said the company is now developing the “ZyPro” line as a “temporary solution” to help alleviate some of the concerns that it was facing in the market.

The new product will be launched in April 2019 and will be priced at 50 million shekels ($8,600) per capsule, according to a press statement.

The announcement comes on the heels of the launch of Otsuki-san, a line of beauty products that is intended to address concerns that the products may be toxic.

The brand has been accused of containing ingredients that may cause severe allergic reactions among some people.

The products, however, were developed in conjunction with AstRAZeneca and OTSUKAS, and are not FDA-approved.